At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
NK cell and PD-1 antibodycombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of NK Cell Combined With PD-1 Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating NK cell and PD-1 antibody for Non-small Cell Lung Cancer. Completed, enrolled 20 participants across 1 site.
Detailed Summary
PD-1 antibody has been approved as second line therapy for driven mutation negative non-small cell lung cancer, but overall response rate is only between 15-20%. Basic study found NK cell can enhance anti-tumor ability of PD-L1 antibody. This study evaluates the efficacy and safety of NK cell combined with PD-1 antibody for advanced driven mutation negative non-small cell lung cancer (NSCLC) as second-line therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartMay 2019
First PostedMay 2019
Primary CompletionOct 2020
Study CompletionOct 2021
TodayJul 2026
First PostedMay 21, 2019
Enrollment StartMay 17, 2019
Primary CompletionOct 21, 2020
Study CompletionOct 21, 2021
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.1 years ago
Interventions
NK cell and PD-1 antibodycombination
Each patient enrolled the study will received both NK cell and PD-1 antibody.